Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) has received the nod from European regulators for the marketing of its drug, providing another avenue of potential for the company as it seeks to successfully land its commercialization effort. The Durham-based company has received European Commission marketing authorization for Doptelet its main drug for the treatment of severe thrombocytopenia in adult patients with chronic liver disease.
Technical Stock Analysis
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a Healthcare sector firm, traded 548829 shares in last trading session and stock rose 3.32% with closing price of $10.59 per share. Company gross margins represents its total sales revenue minus its cost of goods sold (COGS), divided by the total sales revenue earned by the company, expressed as a percentage. And its good to know that the higher that percentage, the more the company retains on each dollar of sales, to service its other costs and the debt obligations, and Dova Pharmaceuticals, Inc. (NASDAQ:DOVA)’s gross margin stands at 88.20%.
Investment Worthy Stock or not?
For personal guess ROI is usually expressed as a percentage and is typically used for taking any financial decisions, for the purpose of comparing a Dova Pharmaceuticals, Inc. (NASDAQ:DOVA)’s profitability or to compare the efficiency of different investments, hence, DOVA return on investment (ROI) is -73.20%.
52-Week Range
52-Week Range are valuable stats for watching Dova Pharmaceuticals, Inc. (NASDAQ:DOVA)’s past year fluctuation as that gives investors an idea of how much the security has moved in the last year and whether it is trading near the top, middle or bottom of the range. Dova Pharmaceuticals, Inc. (NASDAQ:DOVA)’s stock value has moved between $5.63 – 35.3 in last one year.
Analyst’s Views
Analysts mean target price for Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) is $22.50 while analysts mean recommendation is 2.00.
Stock Performance
Its weekly performance is 18.46% while year to date (YTD) performance is 39.71%.
EPS Growth
Earnings per share growth is defined as the percentage change in normalised earnings per share over the previous 12 month period to the latest year end. It gives a good picture of the rate at which a company has grown its profitability. Dova Pharmaceuticals, Inc. (NASDAQ:DOVA)’s EPS growth this year is -86.00%. For best decision making investors should look at Dova Pharmaceuticals, Inc. (NASDAQ:DOVA)’s EPS growth for next year stands at 81.30%.
